Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig M Kessler

Showing results (61-70 of 90) with videos related to

Pageof 9
Sort By:
European Journal of Haematology|March 6, 2018
Impact of hemophilia B on quality of life in affected men, women, and caregivers-Assessment of patient-reported outcomes in the B-HERO-S studyTyler W Buckner, Michelle Witkop, Christine Guelcher, et al.
Research and Practice in Thrombosis and Haemostasis|August 4, 2023
Corrigendum to 'Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis' [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077]Steven W Pipe, Ben Trzaskoma, Miranda Minhas, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 7, 2019
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world settingRebecca Kruse-Jarres, Johannes Oldenburg, Elena Santagostino, et al.
Therapeutic Advances in Hematology|July 3, 2019
Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA programToshko Lissitchkov, Anna Klukowska, John Pasi, et al.
Blood|November 12, 2010
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO modelNeil A Goldenberg, Alex C Spyropoulos, Jonathan L Halperin, et al.
Haematologica|July 2, 2013
Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium TrialRuben A Mesa, Richard T Silver, Srdan Verstovsek, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 23, 2020
Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical companyCharles R M Hay, Midori Shima, Michael Makris, et al.
Thrombosis and Haemostasis|June 28, 2016
Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillationJohn M Kittelson, Philippe Gabriel Steg, Jonathan L Halperin, et al.
Thrombosis Research|June 4, 2017
Feasibility of the Von Willebrand disease PREVENT trialMargaret V Ragni, Nicoletta Machin, Andra H James, et al.
British Journal of Haematology|December 18, 2012
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)Jeffrey I Zwicker, Howard A Liebman, Kenneth A Bauer, et al.
Pageof 9

Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
European Journal of Haematology|March 6, 2018
Impact of hemophilia B on quality of life in affected men, women, and caregivers-Assessment of patient-reported outcomes in the B-HERO-S studyTyler W Buckner, Michelle Witkop, Christine Guelcher, et al.
Research and Practice in Thrombosis and Haemostasis|August 4, 2023
Corrigendum to 'Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis' [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077]Steven W Pipe, Ben Trzaskoma, Miranda Minhas, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 7, 2019
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world settingRebecca Kruse-Jarres, Johannes Oldenburg, Elena Santagostino, et al.
Therapeutic Advances in Hematology|July 3, 2019
Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA programToshko Lissitchkov, Anna Klukowska, John Pasi, et al.
Blood|November 12, 2010
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO modelNeil A Goldenberg, Alex C Spyropoulos, Jonathan L Halperin, et al.
Haematologica|July 2, 2013
Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium TrialRuben A Mesa, Richard T Silver, Srdan Verstovsek, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 23, 2020
Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical companyCharles R M Hay, Midori Shima, Michael Makris, et al.
Thrombosis and Haemostasis|June 28, 2016
Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillationJohn M Kittelson, Philippe Gabriel Steg, Jonathan L Halperin, et al.
Thrombosis Research|June 4, 2017
Feasibility of the Von Willebrand disease PREVENT trialMargaret V Ragni, Nicoletta Machin, Andra H James, et al.
British Journal of Haematology|December 18, 2012
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)Jeffrey I Zwicker, Howard A Liebman, Kenneth A Bauer, et al.
Pageof 9